Initial Results of the eShunt System Presented at the International Society of Hydrocephalus and Cerebrospinal Fluid Disorders Annual meeting in Kobe, Japan
Early development testing results show promise in treating communicating hydrocephalus
September 25, 2017, Boston, MA. CereVasc, LLC, a company focused on improving the care of patients with communicating hydrocephalus announced today the presentation of early test data of its eShunt System at the annual meeting of experts in hydrocephalus diagnosis and treatment held in Kobe, Japan. The podium presentation by Adel Malek, M.D., Ph.D., Director of Neuro-interventional Surgery at Tufts Medical Center, shared the results of bench-top, cadaver and animal testing that led to the development of the current eShunt System, with an audience of world-wide experts at the annual meeting of the International Society of Hydrocephalus and Cerebrospinal Disorders (ISHCSF).
“I was delighted and excited to share our early results with the well-informed audience that attends the ISHCSF meeting,” said Dr. Malek. “There was clear excitement and enthusiasm for the eShunt System minimally invasive approach and many of the delegates attending the meeting indicated their interest in working with us to extend our understanding of the potential advantages of the eShunt System.”
“While it’s still early in the development of this technology, we believe it has the potential to transform the treatment of patients who deal with the shortcomings of our current, 60-year-old open surgical approach,” said Dan Levangie, Chairman of CereVasc, LLC. “We’re very excited by the opportunity to present the eShunt System to this important group experts in the field.”
About CereVasc, LLC
CereVasc, LLC is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Their first product, the eShunt System is an endovascular cerebrospinal fluid (CSF) shunt and associated delivery componentry designed to avoid the need for invasive surgery, general anesthesia and hospitalization associated with the current surgical treatment of communicating hydrocephalus using ventriculo-peritoneal shunts.